What This Means
This research studied a serious complication called early neurological deterioration (END) — meaning a significant worsening of stroke symptoms or death within 72 hours — in patients who underwent a clot-removal procedure called mechanical thrombectomy for stroke. The study looked at 438 patients treated over four years and found that about 1 in 5 patients (19.9%) experienced END. Researchers focused on a brain imaging measurement called CT perfusion (CTP) mismatch volume, which estimates how much brain tissue is at risk of dying but could potentially be saved. Surprisingly, patients with smaller mismatch volumes (less than 75 mL) had the highest rates of END (33%), while those with larger mismatch volumes had lower rates, suggesting the relationship between this imaging measure and outcomes is more complex than previously assumed.
The researchers built two predictive tools to help identify which patients are at highest risk. The first tool, used before the procedure, combined the mismatch volume with three other factors — the size of already-damaged brain tissue (ischemic core), stroke severity on admission, and the quality of blood flow through backup vessels (collateral score). This model performed reasonably well at identifying high-risk patients, with about 38.5% of those classified as high-risk actually experiencing END compared to only 8% in the low-risk group. A second tool was designed for use 24 hours after the procedure for patients who had not yet deteriorated, adding information about whether the blood vessel was successfully reopened and whether any bleeding into the brain had occurred. Notably, one specific type of brain bleeding (parenchymal hematoma) was linked to later deterioration, while a milder type (hemorrhagic infarction) was not.
This research suggests that CT perfusion imaging data, combined with other clinical and imaging factors, can help doctors identify stroke patients most likely to deteriorate after clot removal — both before the procedure and again at the 24-hour mark. Having two separate risk assessment windows may allow for more tailored monitoring and potentially earlier intervention. However, the authors caution that these models were tested only on the same patients used to build them (internal validation), and testing in separate patient groups at other hospitals will be needed before these tools can be widely adopted in clinical practice.